180 related articles for article (PubMed ID: 8882925)
1. Health insurance: coverage of autologous bone marrow transplantation for breast cancer.
Jaggar SF
Oncology (Williston Park); 1996 Sep; 10(9):1329-32, 1337-8, 1340 passim. PubMed ID: 8882925
[No Abstract] [Full Text] [Related]
2. Perspectives. Indefinite results in ABMT (autologous bone marrow transplantation) trials add to challenges for practice standards, quality assurance in cancer care.
Cunningham R
Med Health; 1999 Apr; 53(16):suppl 1-4. PubMed ID: 10387749
[No Abstract] [Full Text] [Related]
3. ABMT and breast cancer.
Firshein J
Healthplan; 1999; 40(4):30-3, 35-7. PubMed ID: 10557735
[No Abstract] [Full Text] [Related]
4. Health insurance coverage for emerging medical technologies: a new approach.
Puzio D
Tort Trial Insur Pract Law J; 2003; 38(4):1019-47. PubMed ID: 14503539
[No Abstract] [Full Text] [Related]
5. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
Edwards S
Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
[No Abstract] [Full Text] [Related]
6. Cancer coverage. Why are insurers paying for this "experimental" therapy?
Med Econ; 1996 Sep; 73(17):38. PubMed ID: 10161873
[No Abstract] [Full Text] [Related]
7. Experimental medical treatments: who should decide coverage?
Collins JC
Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412
[No Abstract] [Full Text] [Related]
8. Experimental medical treatments: who should decide coverage?
Collins JC
Seattle Univ Law Rev; 1997; 20(2):451-87. PubMed ID: 16528856
[No Abstract] [Full Text] [Related]
9. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
Krause KJ
N Engl J Med; 1994 Aug; 331(5):329; author reply 330-1. PubMed ID: 8068113
[No Abstract] [Full Text] [Related]
10. Experimental treatment: can you do the right thing without going broke?
Holoweiko M
Bus Health; 1995 May; 13(5):38-40, 45-6, 48. PubMed ID: 10164496
[No Abstract] [Full Text] [Related]
11. Litigating the science of breast cancer treatment.
Jacobson PD; Rettig RA; Aubry WM
J Health Polit Policy Law; 2007 Oct; 32(5):785-818. PubMed ID: 17855717
[TBL] [Abstract][Full Text] [Related]
12. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
Peters WP; Rogers MC
N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
[TBL] [Abstract][Full Text] [Related]
13. Investigational treatments: coverage, controversy, and consensus.
Ader M
Ann Health Law; 1996; (5):45-60. PubMed ID: 10164521
[No Abstract] [Full Text] [Related]
14. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
Cutler CM; Udvarhelyi IS; Winkenwerder W
N Engl J Med; 1994 Aug; 331(5):329-30. PubMed ID: 8022449
[No Abstract] [Full Text] [Related]
15. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer.
Mello MM; Brennan TA
Health Aff (Millwood); 2001; 20(5):101-17. PubMed ID: 11558695
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow transplants.
Rose LJ
Health Aff (Millwood); 2002; 21(2):308. PubMed ID: 11900184
[No Abstract] [Full Text] [Related]
17. The soul of an HMO.
Larson E
Time; 1996 Jan; 147(4):44-52. PubMed ID: 10153782
[No Abstract] [Full Text] [Related]
18. When an insurer calls your treatment experimental.
Holoweiko M
Med Econ; 1995 Sep; 72(17):171-2, 175-6, 178-82. PubMed ID: 10151340
[No Abstract] [Full Text] [Related]
19. ABMT and breast cancer: what have we learned?
Brown E
Physician Exec; 1999; 25(4):86-8. PubMed ID: 10557495
[TBL] [Abstract][Full Text] [Related]
20. Defining experimental therapy--a third-party payer's dilemma.
Newcomer LN
N Engl J Med; 1990 Dec; 323(24):1702-4. PubMed ID: 2233969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
